[A18-37] Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V

Last updated 06.12.2018

Project no.:
A18-37

Commission:
Commission awarded on 06.06.2018 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Indication:

Treatment-naive adults with advanced renal cell carcinoma (intermediate or poor risk)

Result of dossier assessment:

Intermediate risk: hint of non-quantifiable added benefit in positive MET IHC status; added benefit not proven in other cases; poor risk: added benefit not proven

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Federal Joint Committee (G-BA)

2018-12-06 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.